Literature DB >> 736793

Prevention of CeCl3-induced hepatotoxicity by hypolipidemic compounds.

B Tuchweber, M Salas.   

Abstract

Pretreatment of rats with nafenopin, a hypolipidemic compound, prevents the lethality and hepatotoxicity induced by cerium chloride (CeCl3), a rare earth metal. The increase in hepatic triglycerides and the morphologic changes observed after 48 h of the CeCl3 injection (10 mg/kg) are completely abolished by nafenopin given for 4 days in doses of 250 mg/kg. However, an increase in the frequency of peroxisomes is noted in rats receiving nafenopin and CeCl3, attributable to the hypolipidemic drug pretreatment. In comparing the protective effect of nafenopin with that of CPIB (a structurally related compound) and lentysine (a structurally unrelated agent), it can be seen that nafenopin is about five times more active in decreasing liver triglycerides. The hepatic ultrastructure of rats pretreated with CPIB or lentysine is similar to that of CeCl3-treated controls.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 736793     DOI: 10.1007/bf00354094

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  18 in total

1.  AUTOMATED DETERMINATION OF SERUM TOTAL CHOLESTEROL.

Authors:  J B LEVINE; B ZAK
Journal:  Clin Chim Acta       Date:  1964-10       Impact factor: 3.786

2.  Prevention by steroids of cerium hepatotoxicity.

Authors:  M Salas; B Tuchweber
Journal:  Arch Toxicol       Date:  1976-03-11       Impact factor: 5.153

Review 3.  Possible properties of microbodies (peroxisomes). Microbody proliferation and hypolipidemic drugs.

Authors:  J K Reddy
Journal:  J Histochem Cytochem       Date:  1973-11       Impact factor: 2.479

4.  Microbody proliferation in liver induced by nafenopin, a new hypolipidemic drug: comparison with CPIB.

Authors:  J Reddy; D Svoboda; D Azarnoff
Journal:  Biochem Biophys Res Commun       Date:  1973-05-15       Impact factor: 3.575

5.  Studies on the hepatomegaly caused by the hypolipidemic drugs nafenopin and clofibrate.

Authors:  R B Beckett; R Weiss; R E Stitzel; R J Cenedella
Journal:  Toxicol Appl Pharmacol       Date:  1972-09       Impact factor: 4.219

6.  Effect of clofibrate on the handling of dietary and liver fat.

Authors:  W W Westerfeld; J C Elwood; D A Richert
Journal:  Biochem Pharmacol       Date:  1972-04-15       Impact factor: 5.858

7.  Effect of cerium on the rat liver: an ultrastructural and biochemical study.

Authors:  M Salas; B Tuchweber; K Kovacs; B D Garg
Journal:  Beitr Pathol       Date:  1976-02

8.  Reversal of orotic acid-induced fatty liver in rats by clofibrate.

Authors:  P M Novikoff; D Edelstein
Journal:  Lab Invest       Date:  1977-02       Impact factor: 5.662

9.  Microbodies in experimentally altered cells. II. The relationship of microbody proliferation to endocrine glands.

Authors:  D Svoboda; D Azarnoff; J Reddy
Journal:  J Cell Biol       Date:  1969-03       Impact factor: 10.539

10.  Response of hepatic microbodies to a hypolipidemic agent, ethyl chlorophenoxyisobutyrate (CPIB).

Authors:  D J Svoboda; D L Azarnoff
Journal:  J Cell Biol       Date:  1966-08       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.